Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences, Inc. (FBRX) Income from Continuing Operations (2016 - 2020)

Forte Biosciences (FBRX) has disclosed Income from Continuing Operations for 5 consecutive years, with 4493000.0 as the latest value for Q4 2020.

  • On a quarterly basis, Income from Continuing Operations rose 57.55% to 4493000.0 in Q4 2020 year-over-year; TTM through Dec 2020 was 46980000.0, a 208.96% decrease, with the full-year FY2024 number at 36602000.0, down 12.67% from a year prior.
  • Income from Continuing Operations was 4493000.0 for Q4 2020 at Forte Biosciences, up from 5008000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 14756000.0 in Q2 2019 to a low of 34754000.0 in Q2 2020.
  • A 5-year average of 9326166.67 and a median of 9088000.0 in 2017 define the central range for Income from Continuing Operations.
  • Biggest YoY gain for Income from Continuing Operations was 191.71% in 2019; the steepest drop was 499.22% in 2019.
  • Forte Biosciences' Income from Continuing Operations stood at 8964000.0 in 2016, then decreased by 20.89% to 10837000.0 in 2017, then plummeted by 79.15% to 19414000.0 in 2018, then skyrocketed by 45.49% to 10583000.0 in 2019, then surged by 57.55% to 4493000.0 in 2020.
  • Per Business Quant, the three most recent readings for FBRX's Income from Continuing Operations are 4493000.0 (Q4 2020), 5008000.0 (Q3 2020), and 34754000.0 (Q2 2020).